{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:41Z","timestamp":1790732981065,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isoniazid is metabolized by the N-acetyltransferase 2 (NAT2) enzyme. Individuals classified as slow acetylators are increased risk of developing hepatotoxicity. This study aims to evaluate the clinical and economic impact of incorporating NAT2 genotype-guided dosing of isoniazid to prevent anti-tuberculosis drug-induced hepatitis in the Thai healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A decision tree and Markov model were developed to assess the costs, clinical outcomes, and quality-adjusted life years (QALYs) of NAT2 genotype-guided isoniazid dosing compared to the standard regimen in newly diagnosed pulmonary tuberculosis patients in Thailand. The primary outcomes were costs, QALYs, and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis revealed that the discounted costs for the NAT2 genotype-stratified isoniazid dosing group were 28,538 THB (USD 870), compared to 18,727 THB (USD 570) for the standard regimen. The corresponding discounted QALYs were 9.92\u202fyears and 7.66\u202fyears, respectively. The ICER was 4,333 THB (USD 132) per QALY gained. One-way sensitivity analysis showed that the intervention was cost-effective across all input parameters. Probabilistic sensitivity analysis indicated that 99.98% of simulations were below the threshold for cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Stratified isoniazid dosing by NAT2 genotype would be cost-effective in treatment of pulmonary tuberculosis in Thailand.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1772312","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:39:59Z","timestamp":1774593599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand"],"prefix":"10.3389","volume":"14","author":[{"given":"Mantana","family":"Kantared","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Chiang Mai University","place":["Chiang Mai, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unchalee","family":"Permsuwan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University","place":["Chiang Mai, Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"ref1","volume-title":"National Strategic plan to end TB phase 2 (2023\u20132027)","year":"2023"},{"key":"ref2","volume-title":"Tuberculosis Situation and Activities in Thailand","year":""},{"key":"ref3","volume-title":"NTIP Dashboard","year":""},{"key":"ref4","first-page":"306","article-title":"Anti-tuberculosis regimens after drug-induced hepatitis during TB treatment in Bamrasnaradura infectious diseases institute, 2005\u20132009","volume":"38","author":"Kludpuang","year":"2012","journal-title":"Dis Control J"},{"key":"ref5","first-page":"197","article-title":"Hepatotoxicity from anti-tuberculosis drugs: incidence, mechanism, and management","volume":"7","author":"Thongruang","year":"2012","journal-title":"Thai Pharm Health Sci J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e13795","DOI":"10.1111\/cts.13795","article-title":"Efficacy, safety and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: a systematic review","volume":"17","author":"Surarak","year":"2024","journal-title":"Clin Transl Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12863-024-01286-y","article-title":"Pharmacogenomic insights into tuberculosis treatment show the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis","volume":"25","author":"Mahajan","year":"2024","journal-title":"BMC Genom Data"},{"key":"ref8","first-page":"523","article-title":"NAT2 genotype-guided INH dosage to reduce drug-induced liver injury in Thai patients","volume":"12","author":"Sanchat","year":"2021","journal-title":"Syst Rev Pharm"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1093\/cid\/ciz1212","article-title":"Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis","volume":"71","author":"Rens","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref10","first-page":"58","article-title":"Factors affecting mortality during treatment in pulmonary tuberculosis patients in Surin province, between 2018\u20132022","volume":"31","author":"Sanmai","year":"2025","journal-title":"J Acad Off Dis Prev Control Reg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype-guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref12","volume-title":"National Tuberculosis Control Programme Guideline, Thailand 2021","year":"2021"},{"key":"ref13","volume-title":"NAT2 Report of new Smear-Positive Pulmonary tuberculosis Patients in Health Region 2","year":"2025"},{"key":"ref14","first-page":"274","article-title":"Factors associated with death among tuberculosis patients during treatment at Kanthararom hospital","volume":"3","author":"Phasuknit","year":"2024","journal-title":"Sisaket J Health Res Dev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/FPC.0000000000000552","article-title":"Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort","volume":"35","author":"Amorim","year":"2025","journal-title":"Pharmacogenet Genomics"},{"key":"ref16","volume-title":"Tuberculosis Situation in Thailand","year":""},{"key":"ref17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/IJGM.S16486","article-title":"Time of highest tuberculosis death risk and associated factors: an observation of 12 years in northern Thailand","volume":"4","author":"Moolphate","year":"2011","journal-title":"Int J Gen Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jval.2011.11.006","article-title":"Cost-effectiveness of various tuberculosis control strategies in Thailand","volume":"15","author":"Hunchangsith","year":"2012","journal-title":"Value Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0119332","DOI":"10.1371\/journal.pone.0119332","article-title":"Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors","volume":"10","author":"Chung-Delgado","year":"2015","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.3346\/jkms.2023.38.e167","article-title":"Cost-effectiveness of all-oral regimens for the treatment of multidrug-resistant tuberculosis in Korea: comparison with conventional injectable-containing regimens","volume":"38","author":"Park","year":"2023","journal-title":"J Korean Med Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8266878","DOI":"10.1155\/2022\/8266878","article-title":"Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"J Trop Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e1003566","DOI":"10.1371\/journal.pmed.1003566","article-title":"Dynamics of sputum conversion during effective tuberculosis treatment: a systematic review and meta-analysis","volume":"18","author":"Calderwood","year":"2021","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2055-6640(20)30032-7","article-title":"Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand","volume":"5","author":"Gatechompol","year":"2019","journal-title":"J Virus Erad"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1473-3099(19)30309-3","article-title":"Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis","volume":"19","author":"Romanowski","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e002281","DOI":"10.1136\/bmjresp-2023-002281","article-title":"Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis","volume":"11","author":"Vega","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"ref26","volume-title":"Regulation of Department of Medical Sciences on Service Fees for Laboratory Testing and Services 2019: NAT2-Diplotype Testing using PCR","year":"2019"},{"key":"ref27","volume-title":"Cost-Effectiveness of Investment to End Tuberculosis in Thailand: a Cost-Benefit Analysis","author":"Chawetsan","year":"2017"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/CEOR.S373489","article-title":"Costs associated with adverse drug reactions among HIV\/TB patients in Thailand","volume":"14","author":"Rochanathimoke","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref29","volume-title":"Guideline for Health Technology Assessment in Thailand","author":"Pemsuwan","year":"2021"},{"key":"ref30","first-page":"94","article-title":"Risk factors associated with mortality rates among tuberculosis patients at Banglamung hospital during fiscal years 2016\u20132018","volume":"46","author":"Sumetvathaniya","year":"2020","journal-title":"Dis Control J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"107895","DOI":"10.1016\/j.ijid.2025.107895","article-title":"One-year mortality of tuberculosis patients on isoniazid-based treatment and its association with rapid acetylator NAT2 genotypes","volume":"155","author":"Kasamatsu","year":"2025","journal-title":"Int J Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"659675","DOI":"10.3389\/fphar.2021.659675","article-title":"Health-related quality of life based on EQ-5D utility score in patients with tuberculosis: a systematic review","volume":"12","author":"Park","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jval.2012.09.006","article-title":"A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework","volume":"16","author":"Sadatsafavi","year":"2013","journal-title":"Value Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.5588\/ijtld.15.0158","article-title":"Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India","volume":"19","author":"Suen","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"d5376","DOI":"10.1136\/bmj.d5376","article-title":"Dedicated outreach service for hard-to-reach patients with tuberculosis in London: observational study and economic evaluation","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1772312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:40:01Z","timestamp":1774593601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1772312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2026.1772312"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1772312","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1772312"}}